Trump is about to crash drug prices — and Big Pharma is terrified
Less than a year ago, Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl stated PhRMA would be “answering Trump’s call” to put America first in the healthcare ecosystem. Now, Trump seeks to codify MFN into law, and despite PhRMA’s alleged commitment to accommodating the Trump administration’s affordability agenda, Stephen Ubl has wasted little time in contradicting his own words by voicing his criticism of the decision. Recommended Stories ADF’s war on mail-order abortion I survived the fall of Georgia.
- ▪Less than a year ago, Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl stated PhRMA would be “answering Trump’s call” to put America first in the healthcare ecosystem.
- ▪Now, Trump seeks to codify MFN into law, and despite PhRMA’s alleged commitment to accommodating the Trump administration’s affordability agenda, Stephen Ubl has wasted little time in contradicting his own words by voicing his criticism of
- ▪Recommended Stories ADF’s war on mail-order abortion I survived the fall of Georgia.
Washington Examiner files mainly under politics. We currently carry 2,115 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Washington Examiner |
| Canonical URL | https://www.washingtonexaminer.com/op-eds/4661907/trump-phrma-big-pharma-most-favored-nation-drug-pricing/ |
| Publication time | Mon, 27 Jul 2026 14:00:00 +0000 |
| Retrieval time | 2026-07-27T14:01:23.356Z |
| Last seen | 2026-07-27T14:01:23.356Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | UW8iyRDsotTa · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Less than a year ago, Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl stated PhRMA would be “answering Trump’s call” to put America first in the healthcare ecosystem. However, as President Donald Trump continues to deliver lower prices on medications, PhRMA has not only avoided the call but undermined Trump’s efforts to deliver for Americans.Trump is on the frontlines of the battle to lower prescription prices for the American people through his “Most Favored Nations” (MFN) drug pricing, a policy compelling drug manufacturers to match the price of their products to the lowest price paid by international partners.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
